Rimma S. Mulkidjan

Rimma S. Mulkidjan

Auto-generated profile, based on publicly available information

Rimma S. Mulkidjan

Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 St.-Petersburg, Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
EPElena V. Preobrazhenskaya
Elena V. Preobrazhenskaya
RMRimma S. Mulkidjan
Rimma S. Mulkidjan
FZFyodor A. Zagrebin
Fyodor A. Zagrebin
ARAleksandr Romanko
Aleksandr Romanko
ESEvgeniya S. Saitova
Evgeniya S. Saitova
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
Aim: This study aimed at the identification of new druggable alterations in non-small cell lung carcinomas (NSCLCs). Methods: RNA next generation sequencing (NGS) analysis for 650 protein kinase genes was performed for 89 NSCLCs obtained from young-onset and/or female non-smokers, who were negative for activating events involving EGFR, ALK, ROS1, RET, MET, NTRK1/2/3, BRAF, HER2, KRAS, or NRAS genes. Results: RNA sequencing identified 32 in-frame rearrangements, including 9 instances of fully preserved and 8 tumors with partially preserved tyrosine kinase domains. These 17 translocations were further analyzed in 1,059 mutation-negative NSCLCs, which resulted in the identification of two additional tumors with ADK::KAT6B rearrangement and one carcinoma carrying RPS6KB1::VMP1 fusion. The recently reported CLIP1::LTK gene fusion was tested in 2,754 NSCLCs, which were negative for all known actionable mutations, however, no new instances of this translocation have been observed. We further analyzed RNA sequencing results of 89 NSCLCs for mutations affecting the kinase domain of the involved gene. There were 53 substitutions with a combined annotation dependent depletion (CADD) score above 25; all these lesions turned out to be unique, as the analysis of 551 additional NSCLCs revealed no recurrent alterations. ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each. Conclusions: This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.

28 May 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
RRRinat Raupov
Rinat Raupov
ESE.N. Suspitsyn
E.N. Suspitsyn
EKE.M. Kalashnikova
E.M. Kalashnikova
RMR.C. Mulkidzhan
R.C. Mulkidzhan
AKA.V. Kosmin
A.V. Kosmin
Mikhail KostikMikhail Kostik
Mikhail Kostik
The interferon system (IFN) is a group of signaling molecules with antiviral, antitumor and antiproliferative effects. The most studied signaling pathway is mediated by IFN type I. Mutations of IFN-I-regulated genes are involved in the pathogenesis of systemic lupus erythematosus (SLE). Interferon index (IFN-I-index) – a quantitative indicator of the level of expression of IFN-Iregulated genes – is used to assess the activity of the interferon system. Objective of the study: to assess the level of the IFN-I index in children with SLE, as well as to compare the clinical and laboratory characteristics of patients with high and normal levels of the IFN-I-index. Materials and methods of research: 40 patients (girls – 83%, boys – 17%) under 18 years of age with SLE diagnosed in accordance to the SLICC 2012 criteria were included in a multicenter prospective open uncontrolled nonrandomized continuous study. The age of the patients was 15,2 (12,5 ; 16,7) years. All of them underwent examination and treatment in the Pediatric department № 3 at the clinic of the St. Petersburg State Pediatric Medical University and in the Pediatric department of the Almazov National Medical Research Center. The IFN-I index was determined by real-time PCR with a quantitative assessment of the expression of 5 genes induced by IFN-α and β. Results: aggravated family history of rheumatic diseases was noted in 8 patients: SLE – in 3 (8%), rheumatoid arthritis – in 3 (8%), cold urticaria – in 2 (5%). The average age of onset of the disease is 12 years. The most common clinical manifestations were lesions of the skin, joints, mucous membranes, central nervous system, kidney and fever. 31 patients (78%) had an increased IFN-I index. All cases of kidney failure were observed only in patients with a high IFN index (36% vs 0%, p=0,036). Patients with increased IFN-I-index had statistically significant increased levels of antinuclear (87% vs 56%, p=0,043) and rheumatoid factors (36% vs 0%, p=0,036), higher ECLAM index values (3,0 vs 1.0, p=0,048), ferritin levels (p=0,0008) and, as a consequence, the need for more intensive immunosuppressive therapy (using rituximab and cyclophosphamide) compared with patients with normal IFN-Iindex. A positive statistically significant correlation of the IFN-I index with male sex (r=0,41, p=0,008), nephritis (r=0,35, p=0,026), livedoid rash (r=0,38, p=0,017 ), Raynaud's phenomenon (r=0,37, p=0,018), high antinuclear factor (r=0,82, p=0,001), rheumatoid factor (r=0,654, p=0,011), antibodies to Sm antigen (r=0,57, p=0,034), as well as a negative relationship with anemia (r=–0,67, p=0,009). Conclusion: IFN-I-index can be considered as a surrogate biomarker of activity and prognosis of SLE. Further research is required to validate its diagnostic role.

2 September 2023 in Voprosy onkologii
Verified
Journal Article
Open access
ASAnna Sokolenko
Anna Sokolenko
РБРоберт Бройде
Роберт Бройде
ВНВалерия Ни
Валерия Ни
ТСТатьяна Соколова
Татьяна Соколова
ТГТатьяна Городнова
Татьяна Городнова
ЕИЕвгений Имянитов
Евгений Имянитов

30 April 2025 in Voprosy onkologii
Verified
Journal Article
Open access
ЕСЕвгения Станиславовна Саитова
Евгения Станиславовна Саитова
ФЗФёдор Альбертович Загребин
Фёдор Альбертович Загребин
РМРимма Сергеевна Мулкиджан
Римма Сергеевна Мулкиджан
EPElena V. Preobrazhenskaya
Elena V. Preobrazhenskaya
МСМарина Евгеньевна Симонова
Марина Евгеньевна Симонова
ЕИЕвгений Наумович Имянитов
Евгений Наумович Имянитов
Введение. Микросателлитная нестабильность (MSI) является следствием дефекта системы репарации неспаренных оснований ДНК и сопровождается накоплением множества мутаций в ткани опухоли. Этот феномен характерен для колоректальных опухолей, карцином желудка, рака эндометрия и некоторых других типов новообразований. MSI в опухолях часто сочетается с активацией сигнального пути MAPK, в частности с мутациями в генах KRAS, NRAS и BRAF. Недавние исследования показали, что в опухолях с микросателлитной нестабильностью также могут встречаться транслокации с участием тирозинкиназ ALK, ROS1, RET и NTRK1-3. Цель. Изучить частоту и спектр активирующих транслокаций тирозинкиназ при опухолях разных локализаций с микросателлитной нестабильностью. Материалы и методы. Статус MSI был определен для 27 408 новообразований. Выявление перестроек с участием генов ALK, ROS1, RET и NTRK1-3 в 1284 образцах MSI-позитивных опухолей осуществлялось при помощи тестов по определению несбалансированной экспрессии 5’/3’-концов гена, вариант-специфической ПЦР и высокопроизводительного секвенирования РНК (РНК-NGS). Результаты. Перестройки были обнаружены в 101/990 (10,2 %) случае колоректального рака и 1/108 (1 %) опухоли желудка (ALK: 11; RET: 25; NTRK1: 42; NTRK2: 2; NTRK3: 22), и не были выявлены при раке эндометрия (n = 157), шейки матки (n = 13), поджелудочной железы (n = 7), холангиокарциноме (n = 4) или раке яичника (n = 5). Самой высокой частота транслокаций оказалась среди KRAS/NRAS/BRAF-негативных колоректальных карцином с MSI 93/395 (23,5 %). Гораздо реже перестройки обнаруживались при раке толстой кишки с мутациями KRAS/NRAS/BRAF (8/597, 1,3 %). При раке толстой кишки присутствие транслокаций ассоциировалось с возрастом старше 50 лет ((97/795 (12,2 %) vs 3/195 (1,5 %), p = 0,0002)). Выводы. Транслокации с участием генов тирозинкиназ встречаются со значительной частотой при MSI-позитивном раке толстой кишки, в особенности при KRAS/NRAS/BRAF-негативных опухолях.